Table 1 Characteristics of hip fracture cases and matched controls
From: Statin use and hip fractures in U.S. kidney transplant recipients
Variable | Cases (n = 231) | Controls (n = 15,575) | P-value$ | ||
|---|---|---|---|---|---|
Mean or n | ±SD or % | Mean or n | ±SD or % |  | |
Matched | |||||
 Age (years) (±3 years) | 51.8 | ±12.9 | 51.2 | ±10.4 | 0.09 |
 Median (IQR) | 54 (42–61) |  | 53 (44–58) |  |  |
 Male | 108 | 46.7 | 9308 | 59.8 | - |
 African American | 26 | 11.3 | 1126 | 7.2 | - |
 Time since transplant (±1 year) | 6.9 | ±5.3 | 4.6 | ±4.0 | 0.70 |
 Median (IQR) | 6.1 (2.6–10.0) |  | 3.4 (1.3–7.2) |  |  |
Not Matched | |||||
 Hispanic ethnicity | 42 | 19.0 | 5143 | 33.4 | <0.01 |
 Missing | 10 | 4.3 | 184 | 1.2 |  |
 Body mass index (kg/m2) | 26.0 | ±5.0 | 27.3 | ±5.2 | 0.01 |
 Median (IQR) | 25.0 (22.2–29.3) |  | 26.8 (23.5–30.7) |  |  |
 Missing | 31 | 13.4 | 1417 | 9.1 |  |
 Time since ESRD (years) | 9.9 | ±5.2 | 8.1 | ±4.4 | 0.12 |
 Median (IQR) | 9.3 (5.7–12.9) |  | 7.4 (4.8–10.6) |  |  |
Comorbidities, recorded history of | |||||
 Diabetes mellitus | 195 | 84.4 | 11,594 | 74.4 | <0.01 |
 Cardiovascular disease | 204 | 88.3 | 11,694 | 75.1 | <0.01 |
 Cerebrovascular disease | 101 | 43.7 | 3988 | 25.6 | <0.01 |
 Arrhythmia | 82 | 35.5 | 4205 | 27.0 | 0.14 |
 Rheumatologic disease | 30 | 13.0 | 1382 | 8.9 | 0.32 |
Transplant-related | |||||
 Living (vs. deceased) donor | 56 | 24.2 | 3824 | 24.6 | 0.79 |
 Acute rejection, history of | 32 | 13.9 | 1871 | 12.0 | 0.72 |
 Missing | 0 | 0.0 | 22 | 0.1 |  |
 PRA > 80% | 14 | 7.9 | 824 | 6.2 | 0.59 |
 Missing | 53 | 22.9 | 2285 | 14.7 |  |
Immunosuppressant drugs | |||||
 Tacrolimus | 125 | 54.1 | 9807 | 63.0 | 0.64 |
 Cyclosporine | 71 | 30.7 | 2861 | 18.4 | <0.01 |
 MMF/mycophenolic acid | 153 | 66.2 | 11,138 | 71.5 | 0.20 |
 Azathioprine | 29 | 12.6 | 551 | 3.5 | <0.01 |
 mTor inhibitor | 37 | 16.0 | 1536 | 9.9 | <0.01 |
 Corticosteroid | 187 | 81.0 | 10,681 | 68.6 | <0.01 |
 Bisphosphonate use | 61 | 26.4 | 2111 | 13.6 | <0.01 |